Tyra Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Tyra Biosciences, Inc. (Nasdaq: TYRA) on March 4, 2026. The report discloses a material event under Item 8.01 (Other Events) regarding a significant equity transaction.
Key Financial Metrics
The filing details a specific capital raise event rather than periodic financial performance metrics such as revenue or operating margins.
- Transaction Type: Block transaction under an "at-the-market" offering program.
- Shares Issued: 4,000,000 shares of common stock.
- Purchase Price: $31.50 per share.
- Gross Proceeds: $126.0 million (before fees and expenses).
- Counterparty: A large investment management firm.
Material Changes
The primary material change is the increase in outstanding common stock and the influx of gross proceeds of $126.0 million. The filing does not provide comparative financial data against prior periods as it is a current event report, not a periodic financial statement.
Outlook, Risks, and Management Commentary
The transaction was executed under the Company's existing "at-the-market" offering program registered on Form S-3 (File No. 333-287086) on May 8, 2025. The filing notes that the gross proceeds are subject to deductions for fees and other expenses payable by the Company. No specific forward-looking guidance or risk factors beyond the standard terms of the offering program are detailed in this specific excerpt.
Key Facts for Investor Verification
- Verify the final net proceeds after deducting transaction fees and expenses.
- Confirm the updated total number of outstanding shares post-transaction.
- Review the full sales agreement prospectus dated May 16, 2025, for detailed terms of the "at-the-market" program.
- Assess the impact of the 4,000,000 share issuance on existing shareholder dilution.